Andy Hahn (@onchahn) 's Twitter Profile
Andy Hahn

@onchahn

Genitourinary Medical Oncologist @MDAndersonNews. Opinions are my own.

ID: 807059132033314816

calendar_today09-12-2016 03:07:46

1,1K Tweet

1,1K Followers

465 Following

Andy Hahn (@onchahn) 's Twitter Profile Photo
Andy Hahn
@onchahn

3 months ago

Pasritamig, an hK2 x CD3 bispecific, was remarkably tolerable with low rates of CRS and had encouraging activity in mCRPC in the phase 1 trial.

Pasritamig, an hK2 x CD3 bispecific, was remarkably tolerable with low rates of CRS and had encouraging activity in mCRPC in the phase 1 trial.